Allogene Therapeutics, Inc. (ALLO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 2.9100 |
| Open | 2.9000 |
| Bid | 2.6500 x 500 |
| Ask | 2.6800 x 1900 |
| Day's range | 2.6400 - 2.9700 |
| 52-week range | 2.0100 - 5.7800 |
| Volume | |
| Avg. volume | 2,459,998 |
| Market cap | 556.238M |
| Beta (5Y monthly) | 0.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Allogene Therapeutics Second Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.53 loss in 2Q 2023)
Allogene Therapeutics ( NASDAQ:ALLO ) Second Quarter 2024 Results Key Financial Results Net loss: US$66.4m (loss...
- Zacks
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.
© 2024 Yahoo. All rights reserved.